Jpmorgan Chase & CO In8 Bio, Inc. Transaction History
Jpmorgan Chase & CO
- $1.27 Trillion
- Q1 2025
A detailed history of Jpmorgan Chase & CO transactions in In8 Bio, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 102 shares of INAB stock, worth $235. This represents 0.0% of its overall portfolio holdings.
Number of Shares
102
Previous 112
8.93%
Holding current value
$235
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
11 transactions
Others Institutions Holding INAB
# of Institutions
13Shares Held
2.74MCall Options Held
0Put Options Held
0-
Alyeska Investment Group, L.P. Chicago, IL2.08MShares$4.8 Million0.0% of portfolio
-
Bios Capital Management, LP Fort Worth, TX287KShares$662,1930.83% of portfolio
-
Northern Trust Corp Chicago, IL93.4KShares$215,8000.0% of portfolio
-
State Street Corp Boston, MA88.7KShares$205,0030.0% of portfolio
-
Black Rock Inc. New York, NY57.1KShares$131,8540.0% of portfolio
About IN8BIO, INC.
- Ticker INAB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 24,502,200
- Market Cap $56.6M
- Description
- IN8bio, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidate includes INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of...